Publikationen aus der Klinik

Publikationen aus der Klinik für Hämatologie, Onkologie und Palliativmedizin

Im Jahr 2020
  • Mai E. K., Miah K., Bertsch U., Dürig J., Scheid C., Weisel K. C., Kunz C., Munder M., Lindemann H. W., Merz M., Hose D., Jauch A., Seckinger A., Luntz S., Sauer S., Fuhrmann S., Brossart P., Elmaagacli A., Goerner M., Bernhard H., Hoffmann M., Raab M. S., Blau I. W., Hänel M., Benner A., Salwender H. J., Goldschmidt H., German-speaking Myeloma Multicenter Group (GMMG):
    Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
    Leukemia. 2020 Jul 20. doi: 10.1038/s41375-020-0976-9. Online ahead of print. Leukemia. 2020. PMID: 32684633
  • Goldschmidt H., Mai E. K., Dürig J., Scheid C., Weisel K. C., Kunz C., Bertsch U., Hielscher T., Merz M., Munder M., Lindemann H. W., Hügle-Dörr B., Tichy D., Giesen N., Hose D., Seckinger A., Huhn S., Luntz S., Jauch A., Elmaagacli A., Rabold B., Fuhrmann S., Brossart P., Goerner M., Bernhard H., Hoffmann M., Hillengass J., Raab M. S., Blau I. W., Hänel M., Salwender H. J., German-speaking Myeloma Multicenter Group (GMMG). Goldschmidt H, et al.:
    Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
    Leukemia. 2020 Jul; 34(7):1853-1865. doi: 10.1038/s41375-020-0724-1. Epub 2020 Feb 7. Leukemia. 2020. PMID: 32034285
  • Oppel F., Görner M., Sudhoff H., Oppel F., et al.:
    The Potential of Tumor Debulking to Support Molecular Targeted Therapies
    Front Oncol. 2020 Jun 18; 10:801. doi: 10.3389/fonc.2020.00801. eCollection 2020. Front Oncol. 2020. PMID: 32626653
  • Lorenzen S., Thuss-Patience P., Pauligk C., Goekkurt E., Ettrich T. J., Lordick F., Stahl M., Reichardt P., Soekler M., Pink D., Probst S., Hinke A., Goetze T. O., Al-Batran S. E.:
    FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO
    Journal of Clinical Oncology, Mai 2020, 38 (15_suppl): 4514-4514; DOI: 10.1200/JCO.2020.38.15_suppl.4514
  • Lorenzen S., Knorrenschild J. R., Pauligk C., Hegewisch-Becker S., Seraphin J., Thuss-Patience P., Kopp H. G., Dechow T., Vogel A., Luley K. B., Pink D., Stahl M., Kullmann F., Herbart H., Siveke J., Egger M., Homann N., Probst S., Goetze T. O., Al-Batran S. E.:
    Phase III randomized, double‐blind study of paclitaxel with and without Everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC)
    International Journal of Cancer, April 2020; DOI: 10.1002/ijc.33025
  • Probst S., Biakowksi A.:
    Autonomie und Heimat im Praxis- und Klinikalltag
    In: Gillessen A., Golsabahi-Broclawski S., Biakowski A., Broclawski A. (Hrsg.):
    Interkulturelle Kommunikation in der Medizin
    Buch, 2020, ISBN978-3-662-59011-9, Springer-Verlag Berlin Heidelberg
Im Jahr 2019
  • Al-Batran S.E., Homann N., Pauligk C., Goetze T., Meiler J., Kasper S., Kopp H-G., Mayer F., Haag G.M., Luley K., Lindig U., Schmiegel W., Pohl M., Stoehlmacher J., Folprecht G., Probst S., Prasnikar N. et al.:
    FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Lancet. 2019; Apr 10. pii: S0140-6736(18)32557-1. doi: 10.1016/S0140-6736(18)32557-1. [Epub ahead of print]
  • Probst S.:
    Die palliativmedizinische Begleitung jüdischer Patienten und Palliative Care aus jüdischer Sicht
    Z Palliativmed 2019; 20(1): 31-38
  • Probst S. (Hrsg):
    Hirntod und Organspende aus interkultureller Sicht
    Buch, · 2019, ISBN 978-3-95565-292-0, Hentrich & Hentrich Verlag Berlin Leipzig
  • Probst S., Beaugrand A., Wittkamp K.:
    Memento mori. Meditationen über den Tod. Erfahrungen mit einer Kunstausstellung auf der Palliativstation am Klinikum Bielefeld.
    Spiritual Care. 2019; 8(1):83-89
  • Probst S.:
    Vom Unbehagen jüdischer Familien mit palliativmedizinischen Angeboten
    Schmerzmedizin. 2019; 35(5): 28-31
  • Probst S. (Hrsg):
    Das Antlitz der Alten umschönen – Vom Umgang mit dem Älterwerden und dem Alter
    Buch, · 2019, ISBN 978-3-95565-312-5, Hentrich & Hentrich Verlag Berlin Leipzig
Im Jahr 2018
  • Dietz A., Wichmann G., Kuhnt T., Pfreundner L., Hagen R., Scheich M., Kölbl O., Hautmann M.G., Strutz J., Schreiber F., Bockmühl U., Schilling V., Feyer P., de Wit M., Maschmeyer G., Jungehülsing M., Schroeder U., Wollenberg B., Sittel C., Münter M., Lenarz T., Klussmann J.P., Guntinas-Lichius O., Rudack C., Eich H.T., Foerg T., Preyer S., Westhofen M., Welkoborsky H.J., Esser D., Thurnher D., Remmert S., Sudhoff H., Görner M., Bünzel J., et al.:
    Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II
    Ann Oncol. 2018 Oct 1;29(10):2105-2114. doi: 10.1093/annonc/mdy332.
    https://www.ncbi.nlm.nih.gov/pubmed/30412221
  • Probst S. (Hrsg):
    Vom Umgang mit Verlust und Trauer im Judentum
    Buch, · 2018, ISBN 978-3-95565-247-0, Hentrich & Hentrich Verlag Berlin
  • Probst S.:
    Jüdische Spiritualität in Palliative Care
    Spiritual Care. 2018 7(2):187-189
Im Jahr 2017
  • Al-Batran S.E., Homann N., Pauligk C., Illerhaus G., Martens U.M., Stoehlmacher J., Schmalenberg H., Luley K.B., Prasnikar N., Egger M., Probst S., Messmann H., Moehler M., Fischbach W., Hartmann J.T., Mayer F., Höffkes H.G., Koenigsmann M., Arnold D., Kraus T.W., Grimm K., Berkhoff S., Post S., Jäger E., Bechstein W., Ronellenfitsch U., Mönig S., Hofheinz R-D.:
    Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
    JAMA Oncol. 2017 Sep 1;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515.
    https://www.ncbi.nlm.nih.gov/pubmed/28448662
  • Al-Batran S-E., Pauligk C., Homann N., Schmalenberg H., Kopp H-G., Haag G.M., Luley K., Folprecht G., Probst S., Thuss-Patience P., Trojan J., Koenigsmann M., Lindig U., Pohl M., Kasper S., Möhler M., Goetze T., Schuler M., Jaeger E., Hofheinz R-D.:
    LBA27_PR Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
    Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx440.019,
    https://doi.org/10.1093/annonc/mdx440.019
  • Inhestern J., Schmalenberg H., Dietz A., Rotter N., Maschmeyer G., Jungehülsing M., Grosse-Thie C., Kuhnt T., Görner M., Sudhoff H., Wittekindt C., Guntinas-Lichius O., Inhestern J., et al.:
    A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
    Ann Oncol. 2017 Aug 1; 28(8): 1917-1922. doi: 10.1093/annonc/mdx202. Ann Oncol. 2017. PMID: 28498880
  • Huhn S., Weinhold N., Nickel J., Pritsch M., Hielscher T., Hummel M., Bertsch U., Huegle-Doerr B., Vogel M., Angermund R., Hänel M., Salwender H. J., Weisel K., Dürig J., Görner M., Kirchner H., Peter N., Graeven U., Lordick F., Hoffmann M., Reimer P., Blau I. W., Jauch A., Dembowsky K., Möhler T., Wuchter P., Goldschmidt H.:
    Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
    Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15.
  • Inhestern J., Schmalenberg H., Dietz A., Rotter N., Maschmeyer G., Jungehülsing M., Grosse-Thie C., Kuhnt T., Görner M., Sudhoff H., Wittekindt C., Guntinas-Lichius O.:
    A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
    Ann Oncol. 2017 Aug 1; 28(8):1917-1922. doi: 10.1093/annonc/mdx202.
  • Baertsch M. A., Schlenzka J., Lisenko K., Krzykalla J., Becker N., Weisel K., Noppeney R., Martin H., Lindemann H. W., Haenel M., Nogai A., Scheid C., Salwender H., Fenk R., Graeven U., Reimer P., Schmidt-Hieber M., Goerner M., Schmidt-Wolf I. G. H., Klein S., Ho A. D., Goldschmidt H., Wuchter P.:
    Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
    Eur J Haematol. 2017 Jul;99(1): 42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24.
  • Probst S.:
    Ideal und Wirklichkeit einer „kultursensiblen“ Begleitung Schwerstkranker und Sterbender
    Nervenheilkunde 7/2017; 36: 521–524
  • Al-Batran S-E., Pauligk C., Homann N., Schmalenberg H., Kopp H-G., Haag G.M., Luley K., Schmiegel W.H., Folprecht G., Probst S., Prasnikar N., Thuss-Patience P., Trojan J., Goetze T., Meiler J., Schuler M., Jäger E., Hofheinz R-D.:
    LBA-008 Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
    Annals of Oncology, Volume 28, Issue suppl_3, 1 June 2017, mdx302.007
    https://doi.org/10.1093/annonc/mdx302.007
  • Probst S.:
    Bikkur Cholim Die Begleitung Kranker und Sterbender im Judentum – Bikkur Cholim, jüdische Seelsorge und das jüdische Verständnis von Medizin und Pflege
    Buch, April 2017, ISBN 978-3-95565-213-5, Berlin: Hentrich & Hentrich Verlag
  • Kayser S., Krzykalla J., Elliott M. A., Norsworthy K., Gonzales P., Hills R. K., Baer M. R., Ráčil Z., Mayer J., Novak J., Žák P., Szotkowski T., Grimwade D., Russell N. H., Walter R. B., Estey E. H., Westermann J., Görner M., Benner A., Krämer A., Smith B. D., Burnett A. K., Thiede C., Röllig C., Ho A. D., Ehninger G., Schlenk R. F., Tallman M. S., Levis M. J., Platzbecker U.:
    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
    Leukemia. 2017 Apr 18. doi: 10.1038/leu.2017.92.
  • Brzoska P., Yilmaz-Aslan Y., Probst S.:
    Umgang mit Diversität in der Pflege und Palliativversorgung am Beispiel von Menschen mit Migrationshintergrund
    Z Gerontol Geriat 2017.
    https://doi.org/10.1007/s00391-017-1265-8
  • Al-Batran S-E., Homann N., Schmalenberg H., Kopp H-G., Haag G.M., Luley K., Schmiegel W.H., Folprecht G., Probst S., Prasnikar N., Thuss-Patience P., Fischbach W., Trojan J., Koenigsmann M., Pauligk C., Goetze T., Jaeger E., Meiler J., Schuler M., Hofheinz R-D.:
    Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Conference Paper
    Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004
  • Probst S.:
    Wie gehen wir damit um und was sollen wir antworten, wenn uns unheilbar Kranke um Beihilfe zum Suizid bitten?
    Suizidprophylaxe 44 (2017), Heft 1: 12-17
  • Al-Batran S-E., Riera-Knorrenschild J., Pauligk C., Goetze T., Hegewisch-Becker S., Seraphin J., Thuss-Patience P., Kopp H-G., Dechow T.N., Vogel A., Luley K., Pink D., Stahl M., Kullmann F., Frithjof Hebart H., Siveke J.T., Egger M., Homann N., Probst S., Lorenzen S.:
    A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
    Journal of Clinical Oncology 2017 35:4_suppl, 4-4
  • Al-Batran S-E., Homann N., Schmalenberg H., Kopp H-G., Haag G.M., Luley K., Schmiegel W.H., Folprecht G., Probst S., Prasnikar N., Thuss-Patience P., Fischbach W., Trojan J., Koenigsmann M., Pauligk C., Goetze T., Jäger E., Meiler J., Schuler M., Jäger E., Hofheinz R-D.:
    V683 Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial
    Oncol Res Treat 2017;40(suppl 3):200
  • Lorenzen S., Riera-Knorrenschild J., Pauligk C., Goetze T., Hegewisch-Becker S., Seraphin J., Thuss-Patience P., Kopp H-G., Dechow T.N., Vogel A., Luley K., Pink D., Stahl M., Kullmann F., Frithjof Hebart H., Siveke J.T., Egger M., Homann N., Probst S., Al-Batran S-E.:
    V715 A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
    Journal of Clinical Oncology 2017 35:15_suppl, 4027-4027 Oncol Res Treat 20017;40(suppl 3):208
Im Jahr 2016
  • Müller-Tidow C., Tschanter P., Röllig C., Thiede C., Koschmieder A., Stelljes M., Koschmieder S., Dugas M., Gerss J., Butterfaß-Bahloul T., Wagner R., Eveslage M., Thiem U., Krause S. W., Kaiser U., Kunzmann V., Steffen B., Noppeney R., Herr W., Baldus C. D., Schmitz N., Götze K., Reichle A., Kaufmann M., Neubauer A., Schäfer-Eckart K., Hänel M., Peceny R., Frickhofen N., Kiehl M., Giagounidis A., Görner M., Repp R., Link H., Kiani A., Naumann R., Brümmendorf T. H., Serve H., Ehninger G., Berdel W. E., Krug U., Study Alliance Leukemia Group.:
    Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia
    Leukemia. 2016 Mar; 30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.
  • Rummel M., Kaiser U., Balser C., Stauch M., Brugger W., Welslau M., Niederle N., Losem C., Boeck H. P., Weidmann E., von Gruenhagen U., Mueller L., Sandherr M., Hahn L., Vereshchagina J., Kauff F., Blau W., Hinke A., Barth J., Study Group Indolent Lymphomas:
    Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
    Lancet Oncol. 2016 Jan; 17(1): 57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Erratum in:
    Lancet Oncol. 2016 Jan; 17(1): e6
  • Baertsch M.-A., Schlenzka J., Mai E.K., Merz M., Hillengaß J., Raab M.S., Hose D., Wuchter P., Ho A.D., Jauch A., Hielscher T., Kunz C., Luntz S., Klein S., Schmidt-Wolf I.G.H., Görner M., et.al.:
    Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
    BMC Cancer (2016) 16:290,  DOI 10.1186/s12885-016-2321-2
  • Al-Batran S.E., Hofheinz R.D., Pauligk C., Kopp H.-G., Haag G.M., Luley K.B., Meiler J., Homann N., Lorenzen S., Schmalenberg H., Probst S., Koenigsmann M., Egger M., et al.:
    Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capeciatbine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
    Lancet Oncol (2016), published online October 21, 2016: http://dx.doi.org/10.1016/S1470-2045(16)30531-9
  • Probst S.:
    Nicht alles ist machbar und nicht alles muß gemacht werden. (Buchkapitel)
    In: Klapheck, E. (Hg.):
    Kerrnfragen 1: Jüdische Positionen zur Sterbehilfe.
    Berlin 2016, S. 17-59
  • Inhestern J., Oertel K., Stemmann V., Schmalenberg H., Dietz A., Rotter N., Veit J., Görner M., Sudhoff H., Junghanß C., Wittekindt C., Pachmann K., Gutinas-Lichius O.:
    Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cancer
    PLOS ONE (2015); DOI: 10.1371/journal.pone.0132901
Im Jahr 2015
  • Röllig C., Serve H., Hüttmann A., Noppeney R., Müller-Tidow C., Krug U., Baldus C. D., Brandts C. H., Kunzmann V., Einsele H., Krämer A., Schäfer-Eckart K., Neubauer A., Burchert A., Giagounidis A., Krause S. W., Mackensen A., Aulitzky W., Herbst R., Hänel M., Kiani A., Frickhofen N., Kullmer J., Kaiser U., Link H., Geer T., Reichle A., Junghanß C., Repp R., Heits F., Dürk H., Hase J., Klut I. M., Illmer T., Bornhäuser M., Schaich M., Parmentier S., Görner M., Thiede C., von Bonin M., Schetelig J., Kramer M., Berdel W. E., Ehninger G., Study Alliance Leukaemia:
    Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
    Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6
    https://www.ncbi.nlm.nih.gov/pubmed/26549589
  • Hahn M., Böttcher S., Dietrich S., Hegenbart U., Rieger M., Stadtherr P., Bondong A., Schulz R., Ritgen M., Schmitt T., Tran T. H., Görner M., Herth I., Luft T., Schönland S., Witzens-Harig M., Zenz T., Kneba M., Ho A. D., Dreger P.:
    Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
    Bone Marrow Transplant. 2015 Oct;50(10):1279-85. doi: 10.1038/bmt.2015.150. Epub 2015 Jul 6
  • Hahn M., Böttcher S., Dietrich S., Hegenbart U., Rieger M., Stadtherr P., Bondong A., Schulz R., Ritgen M., Schmitt T., Tran T. H., Görner M., Herth I., Luft T., Schönland S., Witzens-Harig M., Zenz T., Kneba M., Ho A. D., Dreger P.:
    Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
    Bone Marrow Transplant (2015) 50(10):1279-85. doi: 10.1038/bmt.2015.150.
  • Inhestern J., Oertel K., Stemmann V., Schmalenberg H., Dietz A., Rotter N., Veit J., Görner M., Sudhoff H., Junghanß C., Wittekindt C., Pachmann K., Guntinas-Lichius O.:
    Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer
    PLoS One. 2015 Jul 17;10(7):e0132901. doi: 10.1371/journal.pone.0132901. eCollection 2015.
    https://www.ncbi.nlm.nih.gov/pubmed/26186556
  • Pauligk C., Tannpafel A., Meiler J., Luley K.B., Kopp H.-G., Homann N., Hofheinz R.D., Schmalenberg H., Probst S., Haag G.M., et.al.:
    Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of  the FLOT4  phase III study of the AIO
    J Clin Oncol 33, 2015 (suppl; abstr. 4016)
  • Yilmaz-Aslan Y., Annett-Horn A., Gök Y., Probst S., Brzoska P.:
    Palliativversorgung bei Menschen mit Migrationshintergrund: Optimierungspotenziale aus Sicht von Gesundheitspersonal
    Oncol Res Treat 2015; 38 (suppl 2):18
Im Jahr 2014
  • Oettle H., Riess H., Stieler JM., Heil G., Schwaner I., Seraphin J., Görner M., Mölle M., et al.:
    Second-line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folic Acid and Fluorocil Alone for Gemcitabine-Refratory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
    J Clin Oncol. 2014 Aug 10; 32(23):2423-2429. Epub 2014 Jun 30.
  • Herth I., Dietrich S., Benner A., Hegenbarth U., Rieger M., Stadtherr P., Bondong A., Tran TH., Weide R., Hensel M., Knauf W., Franz-Werner J., Welslau M., Procaccianti M., Görner M., Meissner J., Luft T., Schönland S., Witzens-Harig M., Zenz T., Ho AD., Dreger P.:
    The Impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison
    Ann Oncol. 2014 Jan; 25(1):200-6. Doi: 10.1093/annonc/mdt511
Im Jahr 2013
  • Linnemann T., Müller F., Löhnert M., Hirnle P., Görner M.:
    Successful treatment of paraneoplastic hypercalcemia in a patient with giant condyloma acuminatum: a case report
    J Med Case Rep, 2013 Nov 7; 7:251. Doi 10.1186/1752-1947-7-251
  • Shayegi N., Kramer M., Bornhäuser M., Schaich M., Schetelig J., Platzbecker U., Röllig C., Heiderich C., Landt O., Ehninger G., Thiede C.; Study Alliance Leukemia (SAL):
    The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
    Blood. 2013 Jul 4; 122(1):83-92. doi: 10.1182/blood-2012-10-461749. Epub 2013 May 8
    https://pubmed.ncbi.nlm.nih.gov/23656730/
  • Görner M., Brasch F., Hirnle P., Gehl H.B., Scholtz L.U., Wegehenkel K., Sudhoff H.:
    Multimodality treatment for poorly differentiated neuroendocrine head an neck carcinomas – a single institution experience
    Eur J Cancer Care, 2013 May 23. doi: 10.1111/ecc.12070. (Epub ahead of print)
  • Rummel M. J., Niederle N., Maschmeyer G., Banat G. A., von Grünhagen U., Losem C., Kofahl-Krause D., Heil G., Welslau M., Balser C., Kaiser U., Weidmann E., Dürk H., Ballo H., Stauch M., Roller F., Barth J., Hoelzer D., Hinke A., Brugger W.; Study group indolent Lymphomas (StiL):
    Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
    Lancet 2013 Apr 6; 381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6; 381(9873):1184.
    https://pubmed.ncbi.nlm.nih.gov/23433739/
  • Wegehenkel K., Görner M.:
    69-jähriger Patient: Temsirolimus bei progredientem Mantelzell-Lymphom mit Orbitabefall und Zweitmalignom.
    Thieme Case Report, 2013; 1, 13-15
  • Pauligk C., Meiler J., Hofheinz D., Kopp H.-G., Mayer F., Schmalenberg H., Luley K., Haag G. M., Schmiegel W. H., Homann N., Probst S., Königsmann M., Prasnikar N., Trojan J., Egger M., Mahlberg R., Heike M., Tannapfel A., Jäger E., Al-Batran S. E.:
    Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study
    J Clin Oncol 31, 2013 (suppl; abstr 4079)
Im Jahr 2012
  • Al-Batran S.E., Pauligk C., Homann N., Hartmann J.T., Moehler M., Probst S., Rethwisch V., Stoehlmacher-Williams J., Prasnikar N., Hollerbach S., Bokemeyer C., Mahlberg R., Hofheinz R.D., Luley K., Kullmann F., Jäger E.:
    The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
    Eur J Cancer, 2012 Oct 11. pii: S0959-8049 (12)00750-2 doi: 10.1016/j.ejca2012.09.025 (Epub ahead of print)
  • Reddy P. N., Sargin B., Choudhary C., Stein S., Grez M., Müller-Tidow C., Berdel W. E., Serve H., Brandts C. H.; Study Alliance Leukemia (SAL):
    SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control
    Blood. 2012 Aug 23; 120(8):1691-702. Epub 2012 Apr 19
    https://pubmed.ncbi.nlm.nih.gov/22517899/
  • Riesenberg H., Müller F., Görner M.:
    Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report
    J Med Case Rep. 2012 Jul 19;6 (1): 211
  • Hozaeel W., Hofheinz R., Homann N., Illerhaus G., Martens U., Stoelmacher J., Schmalenberg H., Luley K., Prasnikar N., Egger M., Probst S., Fischbach W., Moening S., Hoelscher A.:
    Characteristics of patients with limited metastatic gastric cancer in the FLOT3 trial
    Onkologie 2012; 35(suppl 6): 165
  • Koock U., Pauligk C., Luley K.B., Mayer F., Schulmann K., Homann N., Schmalenberg H., Hozaeel W., Hofheinz R., Probst S., Mahlberg R., Königsmann M., Haag G.M., et al.:
    Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIOJ Clin
    Oncol 30, 2012 (suppl; abstr. 4083)
  • Al-Batran S.E., Hofheinz R., Homann N., Illerhaus G., Martens U.M., Stöhlmacher-Williams J., Schalenberg H., Luley K.B., Prasnikar N., Egger M., Probst S., Hartmann J.T., Möhler M.H., Arnold D., Fischbach W., Pauligk C et al.:
    A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3
    J Clin Oncol 30, 2012 (suppl; abstr. 4090)
Im Jahr 2011
  • Hussein K., Horny H. P., Büsche G., Görner M., Göhring G., Kreipe H., Bock O.:
    Systemic mastocytosis (SM) with associated BCR-ABL-positive myelogenous leukaemia (SM-AHNMD): evidence that mast cells do not belong to the leukaemic clone.
    Leukemia. 2011 Jun; 25(6): 1050-3. doi: 10.1038/leu.2011.41. Epub 2011 Mar 29. No abstract available
    https://pubmed.ncbi.nlm.nih.gov/21445078/
  • Müller F., Riesenberg H., Hirnle P., Gehl H.-B., Düwel P., Görner M.:
    Komplette Remission multifokaler zerebraler Metastasen bei chemotherapierefraktärem NSCLC durch Monotherapie mit Gefitinib
    Strahlentherapie und Onkologie 2011; 12, 826-830
  • Sudhoff H.H., Schwarze H.P., Winder D., Steinstraesser L., Görner M.:
    Evidence for a causal association for HPV in head and neck cancers
    European Archieves of Oto-Rhino-Laryngology, 2011, 268 (11): 1541-1547
  • Al-Batran S., Hofheinz R., Homann N., Illerhaus G., Martens U., Stöhlmacher-Williams J., Schmalenberg H., Luley K., Egger M., Probst S., Hartmann J.T., Arnold D., et al.: Definig two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    J Clin Oncol 29: 2011 (suppl; abstr 4070)
Im Jahr 2010
  • Müller-Tidow C., Klein H. U., Hascher A., Isken F., Tickenbrock L., Thoennissen N., Agrawal-Singh S., Tschanter P., Disselhoff C., Wang Y., Becker A., Thiede C., Ehninger G., zur Stadt U., Koschmieder S., Seidl M., Müller F. U., Schmitz W., Schlenke P., McClelland M., Berdel W. E., Dugas M., Serve H.; Study Alliance Leukemia:
    Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia
    Blood. 2010 Nov 4; 116(18):3564-71. doi: 10.1182/blood-2009-09-240978. Epub 2010 May 24
    https://pubmed.ncbi.nlm.nih.gov/20498303/
  • Görner M., Seiwert T.Y., Sudhoff H.:
    Molecular targeted therapies in head and neck cancer - an update of recent developments
    Head Neck Oncol. 2010, (14) 2-8
  • Al-Batran S.E., Homann N., Hartmann J.T., Möhler M., Pauligk C., Probst S., et al.:
    5-fluorouracil, leucovorin and oxaliplatin with or without docetaxel in elderly  (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the AIO
    J Clin Oncol 28: 15s, 2010 (suppl. abstr 4013)
Im Jahr 2009
  • Bandi S. R., Brandts C., Rensinghoff M., Grundler R., Tickenbrock L., Köhler G., Duyster J., Berdel W. E., Müller-Tidow C., Serve H., Sargin B.; Study Alliance Leukemias:
    E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease
    Blood. 2009 Nov 5; 114(19):4197-208. doi: 10.1182/blood-2008-12-190934. Epub 2009 Sep 4
    https://pubmed.ncbi.nlm.nih.gov/19734451/
  • Seifert H., Mohr B., Thiede C., Oelschlägel U., Schäkel U., Illmer T., Soucek S., Ehninger G., Schaich M.; Study Alliance Leukemia (SAL):
    The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia
    Leukemia. 2009 Apr; 23(4): 656-63. doi: 10.1038/leu.2008.375. Epub 2009 Jan 8
    https://pubmed.ncbi.nlm.nih.gov/19151774/
  • Goon P.K.C.,Stanley M.A., Ebmeyer J., Steinsträsser L., Upile T., Waseem J., Bernal-Sprekelsen M., Görner M., Sudhoff H.H.:
    HPV & head and neck cancer: a descriptive update.
    Head & Neck Oncology 2009; I:36 doi:10.1186/1758-3284-1-36
  • Görner, M., Riemer-Hommel P.:Ökonomische Auswirkungen unterschiedlicher adjuvanter Chemotherapieregime bei Patienten mit Kolonkarzinom im Stadium III
    Onkologie 2009; 32(11) 647
  • Al-Batran S.E., Homann N., Hartmann J.T., Möhler M., Pauligk C., Probst S., Rethwisch V., Prasnikar N., Wagner T., Jäger E.:
    5-Fluorouracil, leucovorin and oxaliplatin with or without docetaxel in older adult patients with esophagogastric cancer: preliminary results from the FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Onkologie 2009; 32 (suppl 4): 135
Im Jahr 2008
  • Al-Batran S.E., Hartmann J.T., Hofheinz R., Homann N., Rethwisch V., Probst S., et al:
    Biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction
    Ann Oncol. 2008 Nov; 19 (11): 1882-1887
  • Görner M., Just M., Gerull S.:
    Mammakarzinom im lokalisierten Stadium – Strategien für die systemisch-adjuvante Therapie
    Handchir Mikrochir Plast Chir, 2008 Aug; 40 (4): 230-238
  • Görner M., Riemer Hommel P.:
    Adjuvant chemotherapy for colon cancer - analysis of treatment costs from the perspective of statutory sickness funds
    Z Gastroenterol. 2008 Jul; 46 (7): 681-688
  • Görner M., Späth-Schwalbe E., Task Force Geriatrische Onkologie of the DGHO, ÖGHO, DGG and AIO:
    Modern treatment options for elderly patients with multiple myeloma
    Onkologie. 2008 Jun; 31 (6): 335-342
  • Görner M., Gerull S., Schäfer E., Just M., Sure M., Hirnle P.:
    Painful spinal cord compression as a complication of extramedullary hematopoiesis associated with beta-thalassemia intermedia
    Strahlenther Onkol., 2008 Apr; 184 (4) 224-226
  • Al-Batran S.E., Hartmann J.T., Probst S., Schmalenberg H., Hollenbach S. et al.:
    Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin
    J Clin Oncol. 2008 Mar 20; 26(9): 1435-1442
  • Al-Batran S., Wirtz R.M., Pauligk C., Steinmetz K., Probst S., Hartmann J.T. et al.:
    Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first line chemotherapy
    J Clin Oncol 26: 2008 (suppl; abstr. 4544)
  • Pauligk C., Wirtz R., Steinmetz K., Probst S., Hartmann J.T., Hofheinz R., Homann N. et al.:
    The prognostic role of the epidermal growth factor receptor (EGFR) in patients with  metastatic gastric cancer.
    J Clin Oncol 26: 2008 (suppl; abstr.22033)
  • Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Görner M., Mölle M., Hilbig A., Dörken B., Riess H., Oettle H.:
    A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
    Onkologie 2008; 31 (suppl 4): 147
Im Jahr 2007
  • Luft T., Conzelmann M., Benner A., Rieger M., Hess M., Strohhaecker U., Görner M., Hegenbart U., Ho A.D., Dreger P.:
    Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease
    Blood 2007, Dec 15; 110 (13): 4535-4542
  • Al-Batran S.E., Hartmann J.T., Hofheinz R., Probst S., Seipelt G., Homann N., Schuch G.:
    Fortgeschrittenes Magenkarzinom
    Onkologisch 3/2007: 10-11
  • Hartmann J.T., Hofheinz R., Clemens M.R., Homann N., Probst S., Pauligk C. Stöhlmacher J et al.:
    Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
    Onkologie, 2007: 30 (suppl 3):139
Im Jahr 2006
Im Jahr 2005
  • Seebach J.D., Stussi G., Passweg J.R., Loberiza FR, Gajewski J.L., Keating A., Görner M., et al.:
    ABO blood group barrier in allogeneic bone marrow transplantation revisted
    Biol Blood Marrow Transplant. 2005 Dec; 11 (12): 1006-1013
  • Bay J.O., Dhedin N., Görner M., Vannier J.P., Marie-Cardine A., Stamatuollas A. et al.:
    Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies
    Transplantation, 2005, Sep. 27; 80 (6): 782-788
  • Raab M.S., Cremer F.W., Breitkreutz I.N., Gerull S., Luft T., Benner A., Görner M., Ho.A.D.:
    Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma
    Ann Oncol. 2005 Apr; 16 (4): 611-617
  • Munder M., Mollinedo F., Calafat J., Canchado J., Gil-Lamaignere C., Fuentes J.M., Luckner C., Doschko G., Soler G., Eichmann K., Müller F.M., Ho A.D., Görner M.:
    Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity
    Blood, 2005 Mar 15; 195 (6): 2549-2556
  • Jahnke K., Thiel E., Schilling A., Herrlinger U., Weller M., Coupland S.E., Krümpelmann U. et al.:
    Low-grade primary central nervous system lymphoma in immunocompetent patients
    Br J Haematol 2005 Mar; 128 (5): 616-624
  • Gerull S., Görner M., Benner A., Hegenbart U. et al.:
    Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma
    Bone Marrow Transplant 2005; 36: 963-969
  • S. Al-Batran, Stöhlmacher J., Probst S., Hollerbach G., Wilhelm G., Derigs H.,  Seipelt G., Kojouharoff G., Graubnaer A., Hinke A., Jäger E.:
    Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluororuracil, leucovorin and cisplatin (FLP) as a first line thearpy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study
    J Clin Oncol, 2005, 23 (suppl. may, abstr. 4015)
Im Jahr 2004
  • Luft T., Maraskovsky E., Schnurr M., Knebel K., Kirsch M., Görner M., Skoda R., Ho A.D., Mawroth P., Bierhaus A.:
    Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells
    Blood. 2004 Aug 15; 104 (4): 1066-1074
  • Müerköster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M. L., Sebens T., Klöppel G., Kalthoff H., Fölsch U. R., Schäfer H., Müerköster S., et al.:
    Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta
    Cancer Res. 2004 Feb 15; 64(4): 1331-7. doi: 10.1158/0008-5472.can-03-1860.
    https://pubmed.ncbi.nlm.nih.gov/14973050/
Im Jahr 2003
  • Luft T., Moos M., Goldschmidt H., Ho A.D., Görner M.:
    Dissociation of putative graf-versus-hematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma
    Br J Haematol. 2003 Nov; 123 (4): 646-653
  • Gerull S., Probst S., Ho A.D., Goldschmidt H., Görner M.,  Schäfer H.:
    Non-myeloablative allogeneictransplantation in patients with high-risk multiple myeloma
    Blood 2003 Nov., 102 (11): 475b
  • Kornacker M., Ipek Y., Probst S., Krasniqi F., Villalobos M, Haas R., Hensel M., Ho A.D.:
    Long term relapse free survival is possible after autologous transplantation for follicular lymphoma
    Blood 2003 Nov., 102 (11): 733a
  • Thomasson B., Peterson L., Thompson J., Görner M., Kiem H.P.:
    Direct comparison of steady-state marrow, primed marrow, and mobilized peripheral blood for transduction of hematopoietic stem cells in dogs
    Hum Gene Ther. 2003 Nov 20; 14 (17): 1683-1686
  • Höpfner S., Görner M., Benner A., Henning P., Ho A.D.:
    Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation
    J Hematother Stem Cell Rex., 2003 Jun; 12 (3): 331 -339
  • Görner M., Weber-Nordt R., Höpfner S., Benner A., Luft T., Ho A.D.:
    Addition of a low fixed number of CD3+ cells to CD34- enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation
    J Hematother Stem Cell Rex., 2003 Jun; 12 (3): 309-320
  • Müerköster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Fölsch U. R., Schäfer H., Müerköster S., et al.:
    Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer
    Int J Cancer. 2003 Apr 20; 104(4): 469-76. doi: 10.1002/ijc.10963.
    https://pubmed.ncbi.nlm.nih.gov/12584745/
  • Leo E., Görner M., Krämer A., Ho A.D.:
    Niedrig- und intermediärmaligne Non-Hodgkin-Lymphome
    Onkologisch 3/2003: 11-15
  • Proske S., Görner M., Schnuch A., Hartschuh W.:
    Analfissuren unter aggressiver Chemotherapie
    Coloproctology, 2003, 25 (2): 106-112